ACT-10041239 is under clinical development by Idorsia Pharmaceutical and currently in Phase I for Multiple Sclerosis.

ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).

Optic Neuritis: Clinical Features Optic neuritis refers to inflammation of the optic nerve. The term may be used broadly in reference to many causes of optic nerve inflammation including systemic ...